系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种自身免疫性疾病,患者血清中可检出多种自身抗体,抗Sm抗体是SLE的标志性抗体,并已成为美国风湿病协会(ARA)1997年修订的诊断标准之一。在Sm抗原中能与抗Sm抗体发生反应的是Sm B/B’和Sm D,而Sm E、F、G及N几乎不与抗Sm抗体起反应。抗Sm B/B’抗体与其它抗RNP抗体存在交叉反应,降低了抗Sm B/B’抗体对SLE诊断的特异性,故抗Sm D抗体被认为是SLE的标志性抗体,而Sm D抗原中最重要的免疫活性蛋白是Sm DI,因此抗Sm D1抗体的检测对SLE的诊断具有重要的作用。 Systemic lupus erythematosus (SLE) is an autoimmune disease that detects multiple autoantibodies in sera. Anti-Sm antibodies are hallmarks of SLE and have been recognized by the American College of Rheumatology (ARA) One of the diagnostic criteria revised in 1997. Sm B / B ’and Sm D which can react with anti-Sm antibodies among Sm antigens, while Sm E, F, G and N hardly react with anti-Sm antibodies. Anti-Sm B / B ’antibodies cross-react with other anti-RNP antibodies, reducing the specificity of anti-Sm B / B’ antibodies for SLE diagnosis. Anti-Sm D antibodies are therefore considered to be SLE’s signature antibodies whereas Sm D antigens The most important immunologically active protein is Sm DI, therefore the detection of anti-Sm D1 antibodies plays an important role in the diagnosis of SLE.